Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright

Genmab A/S (NASDAQ:GMAB) – HC Wainwright issued their Q1 2025 EPS estimates for Genmab A/S in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.18 per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the previous year, the company posted $0.47 earnings per share.

Several other analysts also recently issued reports on the stock. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $21.29 on Friday. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $31.88. The company has a market capitalization of $14.09 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. The firm’s 50-day moving average is $21.07 and its two-hundred day moving average is $23.98.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of GMAB. Two Sigma Advisers LP raised its stake in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Genmab A/S in the second quarter worth $1,354,000. Natixis Advisors LLC increased its position in shares of Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after acquiring an additional 47,437 shares in the last quarter. Finally, FMR LLC increased its position in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.